Global Antiphospholipid Syndrome Score (GAPSS) in patients with primary antiphospholipid syndrome
Stratification of patients into groups of high and low risk of adverse outcome is necessary for timely and early prevention of the disease, as well as the selection of adequate therapy.Objective: to validate the global risk scale for the development of clinical manifestations of antiphospholipid syn...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2023-02-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1385 |
| _version_ | 1797876654028095488 |
|---|---|
| author | F. A. Cheldieva T. M. Reshetnyak A. A. Shumilova K. S. Nurbaeva M. V. Cherkasova E. Yu. Samarkina A. M. Lila |
| author_facet | F. A. Cheldieva T. M. Reshetnyak A. A. Shumilova K. S. Nurbaeva M. V. Cherkasova E. Yu. Samarkina A. M. Lila |
| author_sort | F. A. Cheldieva |
| collection | DOAJ |
| description | Stratification of patients into groups of high and low risk of adverse outcome is necessary for timely and early prevention of the disease, as well as the selection of adequate therapy.Objective: to validate the global risk scale for the development of clinical manifestations of antiphospholipid syndrome (GAPSS) in a cohort of patients with primary antiphospholipid syndrome (PAPS).Material and methods. The study included 64 patients with PAPS. Data on clinical manifestations, traditional cardiovascular risk factors, and antiphospholipid antibody profile were collected. GAPSS values were calculated for each patient by summing the scores corresponding to risk factors as follows: 3 points – for hyperlipidemia; 1 point – for arterial hypertension; 5 points – for antibodies to cardiolipin (aCL) IgG/IgM; 4 points – for antibodies to â2-glycoprotein 1 (anti-â2GP1) IgG/IgM and 3 points – for antibodies to the phosphatidylserine-prothrombin complex (aPS/PT) IgG/IgM.Results and discussion. GAPSS indicators were comparable in women and men with PAPS – 12.0 [9.0; 13.0] points. GAPSS values did not differ in patients with thrombosis and obstetric pathology: in thrombosis they were 10.0±4.46 (range 0.0–14.0) points, in obstetric pathology – 9.26±5.08 (range 0.0–14.0) points.The localization of thrombosis did not affect the GAPSS values, which reached 9.23±5.21 points in arterial thrombosis, 10.44±4.01 points in venous thrombosis, and 10.33±4.18 points in combined ones. Patients with recurrent thrombosis had higher GAPSS scores compared to patients without relapse: 8.19±5.25 points versus 11.00±3.65 points (p=0.01). There were no significant differences in GAPSS scores in obstetric pathology at different gestational ages.GAPSS values ≥6 showed a higher risk of thrombosis recurrence: odds ratio 5.23 (95% CI 1.34–20.37). GAPSS scores ≥6 demonstrated the highest accuracy, with sensitivity and specificity of 72% and 66%, respectively. According to ROC analysis, the AUC value for GAPSS was 0.675 (95% CI 0.542–0.808; p=0.01).Conclusion. The use of GAPSS makes it possible to identify patients at increased risk of recurrent thrombosis. GAPSS scores ≥6 have high sensitivity (72%) and specificity (66%), which can be used to stratify patients with PAPS into high and low risk groups for recurrent thrombosis. |
| first_indexed | 2024-04-10T02:05:08Z |
| format | Article |
| id | doaj.art-341d07bf15fd4fd4bb266975cd6e8bdc |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:05:08Z |
| publishDate | 2023-02-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-341d07bf15fd4fd4bb266975cd6e8bdc2023-03-13T08:39:30ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2023-02-0117110.14412/1996-7012-2023-1-31-372547Global Antiphospholipid Syndrome Score (GAPSS) in patients with primary antiphospholipid syndromeF. A. Cheldieva0T. M. Reshetnyak1A. A. Shumilova2K. S. Nurbaeva3M. V. Cherkasova4E. Yu. Samarkina5A. M. Lila6ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииStratification of patients into groups of high and low risk of adverse outcome is necessary for timely and early prevention of the disease, as well as the selection of adequate therapy.Objective: to validate the global risk scale for the development of clinical manifestations of antiphospholipid syndrome (GAPSS) in a cohort of patients with primary antiphospholipid syndrome (PAPS).Material and methods. The study included 64 patients with PAPS. Data on clinical manifestations, traditional cardiovascular risk factors, and antiphospholipid antibody profile were collected. GAPSS values were calculated for each patient by summing the scores corresponding to risk factors as follows: 3 points – for hyperlipidemia; 1 point – for arterial hypertension; 5 points – for antibodies to cardiolipin (aCL) IgG/IgM; 4 points – for antibodies to â2-glycoprotein 1 (anti-â2GP1) IgG/IgM and 3 points – for antibodies to the phosphatidylserine-prothrombin complex (aPS/PT) IgG/IgM.Results and discussion. GAPSS indicators were comparable in women and men with PAPS – 12.0 [9.0; 13.0] points. GAPSS values did not differ in patients with thrombosis and obstetric pathology: in thrombosis they were 10.0±4.46 (range 0.0–14.0) points, in obstetric pathology – 9.26±5.08 (range 0.0–14.0) points.The localization of thrombosis did not affect the GAPSS values, which reached 9.23±5.21 points in arterial thrombosis, 10.44±4.01 points in venous thrombosis, and 10.33±4.18 points in combined ones. Patients with recurrent thrombosis had higher GAPSS scores compared to patients without relapse: 8.19±5.25 points versus 11.00±3.65 points (p=0.01). There were no significant differences in GAPSS scores in obstetric pathology at different gestational ages.GAPSS values ≥6 showed a higher risk of thrombosis recurrence: odds ratio 5.23 (95% CI 1.34–20.37). GAPSS scores ≥6 demonstrated the highest accuracy, with sensitivity and specificity of 72% and 66%, respectively. According to ROC analysis, the AUC value for GAPSS was 0.675 (95% CI 0.542–0.808; p=0.01).Conclusion. The use of GAPSS makes it possible to identify patients at increased risk of recurrent thrombosis. GAPSS scores ≥6 have high sensitivity (72%) and specificity (66%), which can be used to stratify patients with PAPS into high and low risk groups for recurrent thrombosis.https://mrj.ima-press.net/mrj/article/view/1385глобальная шкала оценки риска развития клинических проявлений антифосфолипидного синдрома (capss)антифосфолипидный синдромантифосфолипидные антителатромбозакушерская патология |
| spellingShingle | F. A. Cheldieva T. M. Reshetnyak A. A. Shumilova K. S. Nurbaeva M. V. Cherkasova E. Yu. Samarkina A. M. Lila Global Antiphospholipid Syndrome Score (GAPSS) in patients with primary antiphospholipid syndrome Современная ревматология глобальная шкала оценки риска развития клинических проявлений антифосфолипидного синдрома (capss) антифосфолипидный синдром антифосфолипидные антитела тромбоз акушерская патология |
| title | Global Antiphospholipid Syndrome Score (GAPSS) in patients with primary antiphospholipid syndrome |
| title_full | Global Antiphospholipid Syndrome Score (GAPSS) in patients with primary antiphospholipid syndrome |
| title_fullStr | Global Antiphospholipid Syndrome Score (GAPSS) in patients with primary antiphospholipid syndrome |
| title_full_unstemmed | Global Antiphospholipid Syndrome Score (GAPSS) in patients with primary antiphospholipid syndrome |
| title_short | Global Antiphospholipid Syndrome Score (GAPSS) in patients with primary antiphospholipid syndrome |
| title_sort | global antiphospholipid syndrome score gapss in patients with primary antiphospholipid syndrome |
| topic | глобальная шкала оценки риска развития клинических проявлений антифосфолипидного синдрома (capss) антифосфолипидный синдром антифосфолипидные антитела тромбоз акушерская патология |
| url | https://mrj.ima-press.net/mrj/article/view/1385 |
| work_keys_str_mv | AT facheldieva globalantiphospholipidsyndromescoregapssinpatientswithprimaryantiphospholipidsyndrome AT tmreshetnyak globalantiphospholipidsyndromescoregapssinpatientswithprimaryantiphospholipidsyndrome AT aashumilova globalantiphospholipidsyndromescoregapssinpatientswithprimaryantiphospholipidsyndrome AT ksnurbaeva globalantiphospholipidsyndromescoregapssinpatientswithprimaryantiphospholipidsyndrome AT mvcherkasova globalantiphospholipidsyndromescoregapssinpatientswithprimaryantiphospholipidsyndrome AT eyusamarkina globalantiphospholipidsyndromescoregapssinpatientswithprimaryantiphospholipidsyndrome AT amlila globalantiphospholipidsyndromescoregapssinpatientswithprimaryantiphospholipidsyndrome |